Patents by Inventor Felix Gonzalez Lopez De Turiso

Felix Gonzalez Lopez De Turiso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240158372
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: August 17, 2023
    Publication date: May 16, 2024
    Inventors: Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
  • Publication number: 20240109867
    Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Application
    Filed: October 5, 2023
    Publication date: April 4, 2024
    Inventors: Felix Gonzalez Lopez de Turiso, Michael Dechantsreiter, Zhili Xin, John H. Jones, Martin Himmelbauer
  • Publication number: 20240083900
    Abstract: Provided are compounds of Formula (I?): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 14, 2024
    Applicant: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Isaac Marx, J├╝rgen Schulz, George Vandeveer, Robin Prince, Marta Nevalainen, TeYu Chen, Zain Yousaf, Martin Himmelbauer, Vatee Pattaropong, John Howard Jones, Edward Yin-Shiang Lin, Felix Gonzalez Lopez de Turiso, Thomas Purgett, Andrew George Capacci, Simone Sciabola
  • Patent number: 11897898
    Abstract: Provided are compounds of Formula (I?), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 13, 2024
    Assignee: BIOGEN MA INC.
    Inventor: Felix Gonzalez Lopez de Turiso
  • Patent number: 11814362
    Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: November 14, 2023
    Assignee: BIOGEN MA INC.
    Inventors: Felix Gonzalez Lopez de Turiso, Michael Dechantsreiter, Zhili Xin, John H. Jones, Martin Himmelbauer
  • Patent number: 11780826
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: October 10, 2023
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent Dimassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Publication number: 20230052348
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
  • Publication number: 20220281850
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 8, 2022
    Inventors: Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
  • Patent number: 11407721
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Michael R. Degraffenreid, Brian M. Fox, Felix Gonzalez Lopez De Turiso, Lisa D. Julian, Frank Kayser, Julio C. Medina, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xuelei Yan
  • Publication number: 20220169611
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Dequette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Josel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Patent number: 11306107
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: April 19, 2022
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, David Karl Bedke, Michael R. Degraffenreid, Jiasheng Fu, Zhihong Li, Felix Gonzalez Lopez De Turiso, Ana Gonzalez Buenrostro, Michael W. Gribble, Jr., Michael G. Johnson, Todd J. Kohn, Kexue Li, Yunxiao Li, Mike Elias Lizarzaburu, Yosup Rew, Joshua Taygerly, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu, Manuel Zancanella, Xian Yun Jiao, Liusheng Zhu, Xianghong Wang, Julio C. Medina, Jason A. Duquette, Jonathan B. Houze, Marc Vimolratana, Mario G. Cardozo, Alan C. Cheng
  • Patent number: 11299479
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 12, 2022
    Assignees: CYTOKINETICS, INC., AMGEN INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Patent number: 11168095
    Abstract: Provided are compounds of Formulas (I?), (I), (II?) and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: November 9, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Felix Gonzalez Lopez de Turiso, Martin Himmelbauer, Michael J. Luzzio
  • Publication number: 20210317103
    Abstract: Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R1, R2, R3, R4 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Application
    Filed: August 13, 2019
    Publication date: October 14, 2021
    Inventors: Felix Gonzalez Lopez de Turiso, Zhili Xin, Martin Himmelbauer, John H. Jones
  • Publication number: 20210300946
    Abstract: Provided are compounds of Formula (I?), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Application
    Filed: August 13, 2019
    Publication date: September 30, 2021
    Inventor: Felix Gonzalez Lopez de Turiso
  • Publication number: 20210179560
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: August 3, 2020
    Publication date: June 17, 2021
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Publication number: 20210115020
    Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Application
    Filed: June 26, 2019
    Publication date: April 22, 2021
    Inventors: Felix Gonzalez Lopez de Turiso, Michael Dechantsreiter, Zhili Xin, John H. Jones, Martin Himmelbauer
  • Patent number: 10899746
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 26, 2021
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Patent number: 10723720
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 28, 2020
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Publication number: 20200223830
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, JR., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson